313 related articles for article (PubMed ID: 23425108)
1. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
Bai M; Yang Z; Qi X; Fan D; Han G
J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
[TBL] [Abstract][Full Text] [Related]
2. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.
Jiang Q; Jiang XH; Zheng MH; Chen YP
J Gastroenterol Hepatol; 2009 Jan; 24(1):9-14. PubMed ID: 18823442
[TBL] [Abstract][Full Text] [Related]
3. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S
J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
[TBL] [Abstract][Full Text] [Related]
6. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Butterworth RF; McPhail MJW
Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis.
Luo M; Li L; Lu CZ; Cao WK
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1250-7. PubMed ID: 21971378
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
Mittal VV; Sharma BC; Sharma P; Sarin SK
Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
10. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S
Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303
[TBL] [Abstract][Full Text] [Related]
11. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.
Soárez PC; Oliveira AC; Padovan J; Parise ER; Ferraz MB
Arq Gastroenterol; 2009; 46(3):241-7. PubMed ID: 19918694
[TBL] [Abstract][Full Text] [Related]
12. [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
Abdo-Francis JM; Pérez-Hernández JL; Hinojosa-Ruiz A; Hernández-Vásquez JR
Rev Gastroenterol Mex; 2010; 75(2):135-41. PubMed ID: 20615780
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Butterworth RF; Kircheis G; Hilger N; McPhail MJW
J Clin Exp Hepatol; 2018 Sep; 8(3):301-313. PubMed ID: 30302048
[TBL] [Abstract][Full Text] [Related]
14. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
Varakanahalli S; Sharma BC; Srivastava S; Sachdeva S; Dahale AS
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385
[TBL] [Abstract][Full Text] [Related]
15. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S
Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
Arab J Gastroenterol; 2024 Feb; ():. PubMed ID: 38403493
[TBL] [Abstract][Full Text] [Related]
17. Normal protein diet and L-ornithine-L-aspartate for hepatic encephalopathy.
Ndraha S; Simadibrata M
Acta Med Indones; 2010 Jul; 42(3):158-61. PubMed ID: 20724770
[TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
Bai M; He C; Yin Z; Niu J; Wang Z; Qi X; Liu L; Yang Z; Guo W; Tie J; Bai W; Xia J; Cai H; Wang J; Wu K; Fan D; Han G
Aliment Pharmacol Ther; 2014 Jul; 40(1):63-71. PubMed ID: 24832463
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Blanco Vela CI; Poo Ramírez JL
Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials.
Cai XJ; Wang L; Hu CM
J Cell Biochem; 2018 Nov; 119(10):8336-8345. PubMed ID: 29932239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
